Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

Rudin CM, Hong K, Streit M.

J Thorac Oncol. 2013 May;8(5):e41-2. doi: 10.1097/JTO.0b013e31828bb1b3. No abstract available.

PMID:
23524406
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Molecular pathology of lung cancer: key to personalized medicine].

Cheng L, Li Y, Zhang SB, Teng XD.

Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):715-20. doi: 10.3760/cma.j.issn.0529-5807.2012.10.019. Review. Chinese. No abstract available.

PMID:
23302321
[PubMed - indexed for MEDLINE]
3.

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.

Cell Death Dis. 2013 Sep 26;4:e814. doi: 10.1038/cddis.2013.312.

PMID:
24071646
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.

Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J.

Lung Cancer. 2013 Nov;82(2):365-7. doi: 10.1016/j.lungcan.2013.08.012. Epub 2013 Aug 19.

PMID:
24035431
[PubMed - indexed for MEDLINE]
5.

[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].

Heneberg P.

Klin Onkol. 2012;25(5):333-9. Review. Czech.

PMID:
23102194
[PubMed - indexed for MEDLINE]
6.

Dabrafenib.

Kainthla R, Kim KB, Falchook GS.

Recent Results Cancer Res. 2014;201:227-40. doi: 10.1007/978-3-642-54490-3_14. Review.

PMID:
24756796
[PubMed - indexed for MEDLINE]
7.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.

PMID:
22773810
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.

Clin Cancer Res. 2011 Mar 1;17(5):1190-9. doi: 10.1158/1078-0432.CCR-10-2331. Epub 2011 Jan 11.

PMID:
21224376
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

ALK, lung cancer, and personalized therapy: portent of the future?

Garber K.

J Natl Cancer Inst. 2010 May 19;102(10):672-5. doi: 10.1093/jnci/djq184. Epub 2010 May 11. No abstract available.

PMID:
20460631
[PubMed - indexed for MEDLINE]
Free Article
10.

The impact of genomic changes on treatment of lung cancer.

Cardarella S, Johnson BE.

Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5. doi: 10.1164/rccm.201305-0843PP. Review.

PMID:
23841470
[PubMed - indexed for MEDLINE]
11.

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.

Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10.

PMID:
23313110
[PubMed - indexed for MEDLINE]
12.

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R.

Oncotarget. 2013 Feb;4(2):310-5.

PMID:
23470635
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J.

J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4. No abstract available.

PMID:
24190114
[PubMed - indexed for MEDLINE]
14.

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.

Park IH, Kim JY, Jung JI, Han JY.

Invest New Drugs. 2010 Dec;28(6):791-9. doi: 10.1007/s10637-009-9319-4. Epub 2009 Sep 17.

PMID:
19760159
[PubMed - indexed for MEDLINE]
15.

Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.

Tuononen K, Mäki-Nevala S, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K, Andrews JM, Telaranta-Keerie AI, Hannula S, Lagström S, Ellonen P, Knuuttila A, Knuutila S.

Genes Chromosomes Cancer. 2013 May;52(5):503-11. doi: 10.1002/gcc.22047. Epub 2013 Jan 30.

PMID:
23362162
[PubMed - indexed for MEDLINE]
17.

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.

Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE.

J Thorac Oncol. 2010 May;5(5):719-20. doi: 10.1097/JTO.0b013e3181d86ebf. No abstract available.

PMID:
20421765
[PubMed - indexed for MEDLINE]
18.

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Gibney GT, Zager JS.

Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. Review.

PMID:
23621583
[PubMed - indexed for MEDLINE]
19.

Dabrafenib: first global approval.

Ballantyne AD, Garnock-Jones KP.

Drugs. 2013 Aug;73(12):1367-76. doi: 10.1007/s40265-013-0095-2.

PMID:
23881668
[PubMed - indexed for MEDLINE]
20.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk